Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

AVAILABLE

Chris O'Brien Lifehouse, Camperdown

AVAILABLE

Peter MacCallum Cancer Centre, Melbourne

AVAILABLE

Fox Chase Cancer Center, Philadelphia

AVAILABLE

L'Istituto Europeo di Oncologia S.r.l., Milan

AVAILABLE

Gregorio Marañón General University Hospital, Madrid

AVAILABLE

GCS IUCT Oncopole, Toulouse

AVAILABLE

CHU de Nantes, Nantes

AVAILABLE

AUSL della Romagna - Ravenna, Ravenna

AVAILABLE

Centre Leon Berard, Lyon

AVAILABLE

National Cheng Kung University Hospital, Tainan City

AVAILABLE

Institut Gustave Roussy, Villejuif

AVAILABLE

National University Hospital Singapore, Singapore

AVAILABLE

National Cancer Centre Singapore, Singapore

AVAILABLE

Massachusetts General Hospital, Boston

AVAILABLE

Dana-Farber Cancer Institute, Boston

AVAILABLE

Princess Margaret Hospital, Toronto

AVAILABLE

Netherlands Cancer Institute: NKI, Amsterdam

AVAILABLE

University Medical Center Groningen, Groningen

AVAILABLE

The Royal Marsden Hospital, Sutton

AVAILABLE

The Christie Hospital, Manchester